Novartis and venture capital firm Versant have set up a new biotech – Borealis Biosciences – using a similar model to their earlier alliance to create Chinook Therapeutics.
Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in
Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share pric
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.